Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FDPS | P14324 | 3/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL393480 | 0.98 | OPRM1 (0.44) | OPRM1LMNADNM1TSHRTHRB | |
| Hexane SCHEMBL1525236 | 0.87 | TSHR (0.50) | OPRM1LMNADNM1TSHRTHRB | |
| Heptane SCHEMBL15226631 | 0.87 | TSHR (0.50) | OPRM1LMNADNM1TSHRTHRB | |
| Hexane SCHEMBL3754301 | 0.87 | TSHR (0.50) | OPRM1LMNADNM1TSHRTHRB | |
| Hexane SCHEMBL17747414 | 0.87 | TSHR (0.50) | OPRM1LMNADNM1TSHRTHRB | |
| SCHEMBL688498 | 0.87 | TSHR (0.50) | OPRM1LMNADNM1TSHRTHRB | |
| Hexane SCHEMBL1145162 | 0.87 | TSHR (0.50) | OPRM1LMNADNM1TSHRTHRB | |
| SCHEMBL16969849 | 0.87 | TSHR (0.50) | OPRM1LMNADNM1TSHRTHRB | |
| SCHEMBL154425 | 0.87 | TSHR (0.50) | OPRM1LMNADNM1TSHRTHRB | |
| SCHEMBL26106 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11904007-B2 | Protection from stress, anxiety, neuroinflammation, and cognitive dysfunction | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-02-20 | — | — | US | disclosed |
| US-20220409714-A1 | Protection from Stress, Anxiety, Neuroinflammation, and Cognitive Dysfunction | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2022-12-29 | — | — | US | disclosed |
| US-20210275659-A1 | Protection from Stress, Anxiety, Neuroinflammation, and Cognitive Dysfunction | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-09-09 | — | — | US | disclosed |
| US-20200297680-A1 | IMMUNOTHERAPEUTIC AGENT | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2020-09-24 | — | — | US | disclosed |
| US-10736864-B2 | Immunotherapeutic agent | IMMODULON THERAPEUTICS LIMITED (GB) | 2020-08-11 | — | — | US | disclosed |
| US-20190167623-A1 | IMMUNOTHERAPEUTIC AGENT | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2019-06-06 | — | — | US | disclosed |
| US-20180185317-A1 | IMMUNOTHERAPEUTIC AGENT | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2018-07-05 | — | — | US | disclosed |
| EP-2604260-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SHIONOGI & CO (JP) | 2017-05-10 | — | — | EP | disclosed |
| US-20160052892-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | SHIONOGI & CO (JP) | 2016-02-25 | — | — | US | disclosed |
| US-9212130-B2 | Heterocyclic derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-6080743-A | AS CHEMICAL INTERMEIDATES FOR PREPARING DRUGS | NOVARTIS AG (CH) | 2000-06-27 | — | — | US | disclosed |
| EP-0985660-A1 | AMINOPHENOL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-5919824-A | Aminophenol derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-07-06 | — | — | US | disclosed |
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | disclosed |
| CN-1178523-A | Aminophenol derivatives | DIICHI PHARMACEUTICAL CO LTD (JP) | 1998-04-08 | — | — | CN | disclosed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| EP-0512352-B1 | Substituted carboxylic acid derivatives | HOFFMANN LA ROCHE (CH) | 1996-03-27 | — | — | EP | disclosed |
| US-5344843-A | Carnitine acryltransferase enzyme inhibitors as antiischemic agents and for cardiovascular disorders | HOFFMAN-LA ROCHE INC. (US) | 1994-09-06 | — | — | US | disclosed |
| US-5231179-A | Heterocyclic compounds and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-07-27 | — | — | US | disclosed |
| EP-0512352-A2 | Substituted carboxylic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167623-A1 | IMMUNOTHERAPEUTIC AGENT | IL2, TSLP, IFNG | OPRM1 2875/4885LMNA 3834/4885DNM1 3301/4885 |
| US-20160052892-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | P2RX3, P2RX6, P2RX2 | OPRM1 112/4885LMNA 2851/4885DNM1 4652/4885 |
| US-10736864-B2 | Immunotherapeutic agent | IL2, TSLP, IFNG | OPRM1 2875/4885LMNA 3834/4885DNM1 3301/4885 |
| US-20200297680-A1 | IMMUNOTHERAPEUTIC AGENT | IL2, TSLP, IFNG | OPRM1 2875/4885LMNA 3834/4885DNM1 3301/4885 |
| US-20180185317-A1 | IMMUNOTHERAPEUTIC AGENT | IL2, TSLP, IFNG | OPRM1 2875/4885LMNA 3834/4885DNM1 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.